Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth

Abstract

Targeting mitochondrial metabolism in cancer cells has shown promising therapeutic potential. Here, the authors screen FDA-approved compound library and show that the β1-blocker nebivolol inhibits oxidative phosphorylation and angiogenesis in cancer cells and can be re-purposed for cancer therapy.